Effects of the Serotonin 5-HT1A Receptor Biased Agonists, F13714 and F15599, on Striatal Neurotransmitter Levels Following l-DOPA Administration in Hemi-Parkinsonian Rats
Peak-dose dyskinesia is associated with the dramatic increase in striatal dopamine levels that follows l-DOPA administration. The ‘false neurotransmitter’ hypothesis postulates that the latter is likely due to an aberrant processing of l-DOPA by serotonergic neurons. In keeping with this hypothesis, two highly selective ‘biased agonists’ of 5-HT1A receptors—namely F13714 and F15599 (NLX-101)—were recently shown to exhibit exceptionally potent anti-dyskinetic activity without impairing l-DOPA therapeutic properties despite their differential targeting of 5-HT1A receptor sub-populations. In this study, we investigated whether these two compounds dampened peak l-DOPA-induced dopamine microdialysate levels in the striatum of hemi-parkinsonian rats. Acute administration of either F13714 (0.04 and 0.16 mg/kg i.p.) or F15599 (0.16 and 0.64 mg/kg, i.p.) blunted l-DOPA (2 mg/kg)-induced increases in dopamine microdialysate levels in the denervated striatum (following unilateral injection of 6-OHDA into the medial forebrain bundle). No significant changes were observed on the intact side of the brain. Concurrently, both drugs profoundly reduced striatal serotonin levels on both sides of the brain. In addition, F13714 and F15599, in the presence of l-DOPA, produced a dose-dependent increase in glutamate levels, but this effect was restricted to later time points. These finding support the interpretation that F13714 and F15599 mediate their anti-dyskinetic effects by blunting of the peak in dopamine levels via activation of somatodendritic serotonin 5-HT1A receptors and the consequent inhibition of serotonergic neurons. This study adds to the growing body of evidence supporting the development of a potent 5-HT1A receptor agonist for treatment of peak-dose dyskinesia.
Keywords5-HT1A receptors Dopamine Dyskinesia Glutamate Parkinson’s disease Serotonin
We gratefully acknowledge the financial support of the Michael J. Fox Foundation for Parkinson’s Research and in vivo and bioanalytical support of the respective teams at Brain OnLine B.V. We thank Alexandre Seillier for assistance in preparation of the manuscript.
Compliance with Ethical Standards
Conflict of interest
Adrian Newman-Tancredi and Mark A. Varney are employees of Neurolixis Inc. At the time the studies were conducted, Andrew C. McCreary was an employee of Brain OnLine B.V.
- 28.Assie MB, Lomenech H, Ravailhe V, Faucillon V, Newman-Tancredi A (2006) Rapid desensitization of somatodendritic 5-HT1A receptors by chronic administration of the high-efficacy 5-HT1A agonist, F13714: a microdialysis study in the rat. Br J Pharmacol 149:170–178CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Newman-Tancredi A, Martel JC, Assie MB, Buritova J, Lauressergues E, Cosi C, Heusler P, Bruins Slot L, Colpaert FC, Vacher B, Cussac D (2009) Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist. Br J Pharmacol 156:338–353CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Paxinos G, Watson C (2007) The rat brain in stereotaxic coordinates. Academic Press, CambridgeGoogle Scholar
- 40.Kannari K, Yamato H, Shen H, Tomiyama M, Suda T, Matsunaga M (2001) Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered l-DOPA in the striatum with nigrostriatal denervation. J Neurochem 76:1346–1353CrossRefPubMedGoogle Scholar
- 57.Assie MB, Bardin L, Auclair AL, Carilla-Durand E, Depoortere R, Koek W, Kleven MS, Colpaert F, Vacher B, Newman-Tancredi A (2010) F15599, a highly selective post-synaptic 5-HT1A receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity. Int J Neuropsychopharmacol 13:1285–1298CrossRefPubMedGoogle Scholar
- 60.Assié M-B, Ravailhe V, Benas C, Newman-Tancredi A (2008) Differential effects of 5-HT1A receptor agonists on extracellular levels of 5-HT in hippocampus and of dopamine in frontal cortex of freely moving rats. In: British Association for Psychopharmacology Summer Meeting. Harrogate, Poster ID 59Google Scholar